United Therapeutics CEO Rothblatt Executes Options and Sells Shares Under 10b5-1
Rhea-AI Filing Summary
United Therapeutics (UTHR) insider activity: Martine A. Rothblatt, Chairperson & CEO, exercised 8,000 stock options at an exercise price of $120.26 on 09/09/2025 and sold two blocks of common stock totaling 8,000 shares (6,165 shares at a weighted average price of $398.285 and 1,835 shares at a weighted average price of $399.4263). The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan established May 2, 2025, covering a tranche of 294,000 stock options that expire March 15, 2026 and continuing until exhaustion of that tranche or December 31, 2025. The Form 4 reports direct and indirect holdings via spouse and family trusts as disclosed.
Positive
- Transactions executed under a 10b5-1 plan, indicating pre-arranged, documented trading intent
- Full disclosure of indirect holdings through spouse and family trusts, enhancing transparency
Negative
- Insider sold 8,000 shares, which may be perceived as liquidity-taking by the CEO
- Continued potential for further sales from a tranche of 294,000 options expiring March 15, 2026
Insights
TL;DR: Insider exercised options and sold shares under a documented 10b5-1 plan, which aligns with routine, pre-planned disposition.
The filing shows an exercise of 8,000 options at $120.26 and subsequent sales of 8,000 shares at weighted average prices near $398-$399 executed under a 10b5-1 plan dated May 2, 2025. Use of a 10b5-1 plan reduces immediate concerns about opportunistic timing but does not eliminate the need to monitor ongoing filings for tranche exhaustion and additional sales. Disclosures of indirect holdings through spouse and family trusts are consistent with standard governance transparency.
TL;DR: The transactions are material only as routine insider liquidity; they do not, by themselves, indicate a change in company fundamentals.
The reporting person converted options into 8,000 shares and sold those shares in multiple trades at weighted average prices of $398.285 and $399.4263. The plan covers up to 294,000 options expiring March 15, 2026 or through December 31, 2025, which could lead to additional, planned sales. Investors should note the magnitude relative to total outstanding shares is not provided in this filing, so market impact cannot be assessed from this Form 4 alone.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 8,000 | $0.00 | -- |
| Exercise | Common Stock | 8,000 | $120.26 | $962K |
| Sale | Common Stock | 6,165 | $398.285 | $2.46M |
| Sale | Common Stock | 1,835 | $399.4263 | $733K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025. This transaction was executed in multiple trades at prices ranging from $397.89 to $398.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $398.92 to $399.485. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
